Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery.

Gene therapy has shown a tremendous potential to benefit patients in a variety of disease conditions. However, finding a safe and effective systemic delivery system is the major obstacle in this area. Although viral vectors showed promise for high transfection rate, the immunogenicity associated with these systems has hindered further development. As an alternative to viral gene delivery, this review focuses on application of novel safe and effective non-condensing polymeric systems that have shown high transgene expression when administered systemically or by the oral route. Type B gelatin-based engineered nanocarriers were evaluated for passive and active tumor-targeted delivery and transfection using both reporter and therapeutic plasmid DNA. Additionally, we have shown that nanoparticles-in-microsphere oral system (NiMOS) can efficiently deliver reporter and therapeutic gene constructs in the gastrointestinal tract. Additionally, there has been a significant recent interest in the use small interfering RNA (siRNA) as a therapeutic system for gene silencing. Both gelatin nanoparticles and NiMOS have shown activity in systemic and oral delivery of siRNA, respectively.

[1]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[2]  Kohei Tahara,et al.  Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects , 2009, European Journal of Pharmaceutics and Biopharmaceutics.

[3]  L. Seymour,et al.  Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectors. , 2002, Journal of the American Chemical Society.

[4]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[5]  J. Benoit,et al.  Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. , 2008, Biomaterials.

[6]  Junfeng Zhang,et al.  A pH/enzyme-responsive tumor-specific delivery system for doxorubicin. , 2010, Biomaterials.

[7]  F. Brennan,et al.  IL-10 Gene Therapy Is Therapeutic for Dextran Sodium Sulfate-Induced Murine Colitis , 2004, Digestive Diseases and Sciences.

[8]  Aliasger K Salem,et al.  Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. , 2008, Journal of pharmaceutical sciences.

[9]  C. L. Silva,et al.  Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis , 2003, Gene Therapy.

[10]  Jin-Zhi Du,et al.  A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. , 2011, Biomaterials.

[11]  R. Proulx,et al.  A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle , 2000, Gene Therapy.

[12]  Anton P. McCaffrey,et al.  In vivo activity of nuclease-resistant siRNAs. , 2004, RNA.

[13]  Jindrich Kopecek,et al.  Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. , 2002, Advanced drug delivery reviews.

[14]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[15]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[16]  M. Alonso,et al.  PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery. , 2005, Biomacromolecules.

[17]  D. H. Napper Polymeric stabilization of colloidal dispersions , 1983 .

[18]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[19]  M. Amiji,et al.  Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.

[20]  Hannah Hoag Gene therapy rising? , 2005, Nature.

[21]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[22]  Mansoor Amiji,et al.  Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Mansoor Amiji,et al.  Long-Circulating Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles for Intracellular Delivery , 2002, Pharmaceutical Research.

[24]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[25]  Mansoor M Amiji,et al.  Polymeric nano- and microparticle technologies for oral gene delivery , 2007, Expert opinion on drug delivery.

[26]  X. Shuai,et al.  Supramolecular gene delivery vectors showing enhanced transgene expression and good biocompatibility. , 2005, Bioconjugate chemistry.

[27]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[28]  M. Amiji,et al.  Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors , 2007, Cancer Gene Therapy.

[29]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[30]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[31]  H. Okada,et al.  Biodegradable microspheres in drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.

[32]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[33]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[34]  A. Vila,et al.  PLA-PEG particles as nasal protein carriers: the influence of the particle size. , 2005, International journal of pharmaceutics.

[35]  Mansoor M Amiji,et al.  Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[36]  R. Johnson,et al.  Safety toxicity study of plasmid‐based IL‐12 therapy in Cynomolgus monkeys , 2002, The Journal of pharmacy and pharmacology.

[37]  Allan Hoffman,et al.  A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Mansoor M. Amiji,et al.  Polymeric Gene Delivery : Principles and Applications , 2004 .

[39]  H. Merkle,et al.  Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[40]  A. Kabanov,et al.  Self-assembling complexes for gene delivery : from laboratory to clinical trial , 1998 .

[41]  J. Nah,et al.  A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier. , 2007, Biomaterials.

[42]  D. Bazile,et al.  Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. , 1996, Biomaterials.

[43]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[44]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[45]  S. B. Tiwari,et al.  Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Antonios G Mikos,et al.  Gelatin as a delivery vehicle for the controlled release of bioactive molecules. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[47]  R. Mumper,et al.  Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine. , 1998, Human gene therapy.

[48]  Guohua Jiang,et al.  Degradable, pH-sensitive, membrane-destabilizing, comb-like polymers for intracellular delivery of nucleic acids. , 2010, Biomaterials.

[49]  G. Kwon,et al.  Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. , 2002, Journal of biomedical materials research.

[50]  M. Amiji,et al.  Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[51]  Kenneth A Howard,et al.  Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  D. Fischer,et al.  The Structure of PEG-Modified Poly(Ethylene Imines) Influences Biodistribution and Pharmacokinetics of Their Complexes with NF-κB Decoy in Mice , 2002, Pharmaceutical Research.

[53]  F. Brennan,et al.  IL-10 gene therapy prevents TNBS-induced colitis , 2002, Gene Therapy.

[54]  M. Woodle,et al.  Harnessing in vivo siRNA delivery for drug discovery and therapeutic development , 2006, Drug Discovery Today.

[55]  R. Mumper,et al.  Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Shao-heng He,et al.  IL-10 and its related cytokines for treatment of inflammatory bowel disease. , 2004, World journal of gastroenterology.

[57]  Mansoor Amiji,et al.  Biodistribution and Targeting Potential of Poly(ethylene glycol)-modified Gelatin Nanoparticles in Subcutaneous Murine Tumor Model , 2004, Journal of drug targeting.

[58]  T. Hollon Researchers and regulators reflect on first gene therapy death. , 2000, Nature medicine.

[59]  Alexander V Kabanov,et al.  Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[60]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[61]  C. McCormick,et al.  Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. , 2008, Advanced drug delivery reviews.

[62]  Mansoor Amiji,et al.  Tumor-Targeted Gene Delivery Using Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.

[63]  Alexander V Kabanov,et al.  Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. , 2002, Critical reviews in therapeutic drug carrier systems.

[64]  S. B. Tiwari,et al.  Long-Circulating Polymeric Nanovectors for Tumor-Selective Gene Delivery , 2005, Technology in cancer research & treatment.

[65]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[66]  M. Amiji,et al.  Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. , 2005, Bioconjugate chemistry.

[67]  M. Wientjes,et al.  Determinants of drug delivery and transport to solid tumors. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[68]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[69]  M. Amiji,et al.  Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease , 2008, Gene Therapy.

[70]  Masato Nakamura,et al.  Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. , 2003, International journal of molecular medicine.

[71]  T. Park,et al.  Multifunctional siRNA delivery system: Polyelectrolyte complex micelles of six‐arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide , 2009, Biotechnology progress.

[72]  J. Carretero,et al.  Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. , 1999, Free radical biology & medicine.

[73]  M. Woodle,et al.  Advances in Systemic siRNA Delivery. , 2009, Drugs of the future.

[74]  Terry W. J. Steele,et al.  A new synthesis method and degradation of hyper-branched polyethylenimine grafted polycaprolactone block mono-methoxyl poly (ethylene glycol) copolymers (hy-PEI-g-PCL-b-mPEG) as potential DNA delivery vectors , 2009 .

[75]  Mansoor Amiji,et al.  Epidermal Growth Factor Receptor-Targeted Gelatin-Based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells , 2008, The AAPS Journal.

[76]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[77]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[78]  Y. Omidi,et al.  Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. , 2005, Current drug delivery.

[79]  Leaf Huang,et al.  Nonviral gene therapy: promises and challenges , 2000, Gene Therapy.

[80]  J. Clegg,et al.  Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. , 1997, Vaccine.

[81]  Pierre Lemieux,et al.  Block copolymeric biotransport carriers as versatile vehicles for drug delivery , 2001, Expert opinion on investigational drugs.

[82]  F. Huang,et al.  Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers. , 2010, Biomacromolecules.

[83]  Allan C. deCamp,et al.  A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults. , 2009, Vaccine.

[84]  H. Chung,et al.  Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[85]  Shruti N. Shah Hypoxia in Tumor Angiogenesis and Metastasis: Evaluation of VEGF and MMP Over-expression and Down-Regulation of HIF-1alpha with RNAi in Hypoxic Tumor Cells , 2010 .

[86]  Jeong-Sook Park,et al.  Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. , 2010, International journal of pharmaceutics.

[87]  A. Vila,et al.  Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[88]  Khursheed Anwer,et al.  Polyvinyl Derivatives as Novel Interactive Polymers for Controlled Gene Delivery to Muscle , 1996, Pharmaceutical Research.